A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis - Trial NCT06254950
Access comprehensive clinical trial information for NCT06254950 through Pure Global AI's free database. This Phase 2 trial is sponsored by Takeda and is currently Not yet recruiting. The study focuses on Ulcerative Colitis. Target enrollment is 207 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Takeda
Timeline & Enrollment
Phase 2
Apr 12, 2024
Aug 04, 2027
Primary Outcome
Percentage of Participants Achieving Clinical Remission at Week 12 Based on Modified Mayo Score (mMS)
Summary
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms
 compared to placebo. Another aim is to compare any medical problems that participants have
 when they take TAK-279 or placebo and how well the participants tolerate any problems.
 
 The participants will take capsules of either TAK-279 or placebo for up to 3 months (12
 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of
 the study (1 year or 52 weeks).
 
 During the study, participants will visit their study clinic several times.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06254950
Non-Device Trial